A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

Also called NCT06972732

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 204 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06972732
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06972732. Randomized; no masking; primary purpose treatment. Start 2025-06-11 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Acronym
TELOS
Intervention (Drug)
Metformin
Intervention (Drug)
Dapagliflozin/Pioglitazone
Intervention (Drug)
Dapagliflozin/Sitagliptin
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06972732
Content hash
39df9c773cc1af3fe1d27b38c3cd1457db781d25c1a71ceaff092ca40b06a8ca